Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gentelbull topical gentamicin study in epidermolysis bullosa
2020-002337-15Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Jun 2020
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of gentamicin in epidermolysis bullosa (EB) (3 arms), sponsored by Oslo University Hospital. Primary endpoint: Change in total wound area at week 6. Started Jun 2020; status: completed.
02
Drugs
gentamicin
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on 2020-002337-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002337-15.